GALDERMA
8.3.2019 15:02:05 CET | Business Wire | Press release
Galderma, Nestlé Skin Health’s medical solutions business, presented the final results from a Phase 2b dose-ranging study of nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis (AD), at the late-breaking session of the 2019 American Academy of Dermatology annual meeting (March 1-5).
Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that plays a key role in the pathogenesis of moderate-to-severe AD.
Moderate to severe AD is a serious, chronic form of eczema associated with a high burden of disease linked to itch, sleep deprivation and significant quality of life impairment. This double blind, placebo-controlled, 24 week, dose-ranging Phase 2b study enrolled 226 subjects with moderate-to-severe AD not adequately controlled with topical corticosteroids. All groups received concomitant topical corticotherapy.
This study met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared with placebo. A 73 percent reduction in mean EASI score was observed at Week 24 with nemolizumab compared with 58 percent for placebo.
Nemolizumab was well-tolerated across all dose levels in this trial. The most common adverse events observed were nasopharyngitis and upper respiratory tract infection. Subjects with pre-existing asthma reported an increase in asthma related events; these events were mostly mild and were reversible under treatment.
Nemolizumab-treated subjects showed statistically significant improvements in key secondary efficacy measures compared with placebo after 16 weeks of treatment:
- 33 percent of nemolizumab-treated subjects achieved clear or almost-clear skin as measured by an investigator’s global assessment (IGA) score of 0 or 1, compared with 12 percent of placebo-treated subjects (p=0.008);
- 49 percent of nemolizumab-treated subjects achieved 75 percent reduction in EASI score compared with 19 percent of placebo-treated subjects (p<0.01); and
- 68 percent of nemolizumab-treated subjects achieved at least 4-point reduction in itch, as measured by the pruritus numerical-rating scale (NRS) score, compared with 21 percent reduction in placebo-treated subjects. (p<0.001).
In addition, nemolizumab was associated with a rapid onset of action on AD symptoms: nemolizumab-treated subjects showed early statistically significant improvements in itching and sleep compared with placebo-treated subjects as measured by pruritus NRS and sleep disturbance NRS.
“We are excited by this Phase 2b late-breaking presentation and to be able to report that nemolizumab met all study endpoints in treatment of moderate to severe atopic dermatitis. These new data have added to growing evidence generated with our partner, Chugai, highlighting the importance of the IL-31 pathway as a key driver in moderate to severe atopic dermatitis,” said Thibaud Portal, Ph. D., Global Vice President of Galderma’s Prescription Business.
“The results of this Phase 2b study showed that nemolizumab significantly improved atopic dermatitis signs and very rapidly improved atopic dermatitis symptoms, including pruritus and sleep disturbance. These findings show why nemolizumab is such a promising new investigational drug and how it could be helpful in treating moderate to severe atopic dermatitis,” said Dr. Jonathan I Silverberg, Principal Investigator of the Phase 2b program, from the Department of Dermatology, North Western University, Chicago, IL, USA.
Galderma is now actively preparing for a worldwide Phase 3 pivotal program which will be implemented by mid-2019.
About the IL-31 Pathway and Atopic Dermatitis
Moderate-to-severe
atopic dermatitis (AD), a serious, chronic form of eczema, is a systemic
inflammatory disease characterized by an allergic response driven by a
subset of immune cells called Type 2 helper T cells, or Th2 cells.
IL-31, a cytokine released by Th2 cells, is involved in AD associated
pruritus by interacting with IL-31 receptor alpha expressed by neuron.
IL-31 is also thought to play a role in AD skin inflammation and AD skin
barrier impairment. Moderate-to-severe forms of AD can be characterized
by pronounced cutaneous dryness, and skin lesions marked by redness,
infiltration/papulation, crusting/oozing, and lichenification, with
periods of lesion exacerbation accompanied by intense itching,
scratching, and skin damage that can lead to secondary infections.
Moderate-to-severe AD can negatively impact patients’ lives and is
associated with a high burden to patients particularly with itching,
sleep deprivation and depression.
About Nemolizumab
Nemolizumab, a first-in-class humanized
monoclonal antibody, is directed against the IL-31R alpha, which blocks
signaling from both IL-31. Nemolizumab, initially developed by Chugai,
was subsequently licensed to Nestlé Skin Health in 2016. Nemolizumab is
an investigational agent under clinical development and its safety and
efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma, Nestlé Skin Health’s medical
solutions business, was created in 1981 and is now present in over 100
countries with an extensive product portfolio to treat a range of
dermatological conditions. The company partners with health care
practitioners around the world to meet the skin health needs of people
throughout their lifetime. Galderma is a leader in research and
development of scientifically-defined and medically-proven solutions for
the skin. For more information, please visit www.galderma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190308005203/en/
Contact:
Media : Sébastien Cros, Head of Corporate Communications info@nestleskinhealth.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release
Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release
Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release
Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release
The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release
Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
